SCHEMBL13912971

SCHEMBL13912971

CC(C)(C)CCNCCCCO

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TDP1 Q9NUW8 1/20 0.38
ALDH1A1 P00352 3/20 0.36
TSHR P16473 2/20 0.36
CYP2C19 P33261 3/20 0.35
CYP1A2 P05177 2/20 0.35
KDM4E B2RXH2 1/20 0.33
CA2 P00918 4/20 0.32
CA1 P00915 3/20 0.32
CA12 O43570 3/20 0.32
CA9 Q16790 3/20 0.32
SMN1; SMN2 Q16637 1/20 0.32
MEN1 O00255 3/20 0.31
KMT2A Q03164 3/20 0.31
ALOX15 P16050 2/20 0.31
LMNA P02545 2/20 0.31
HSD17B10 Q99714 2/20 0.31
TP53 P04637 1/20 0.31
F13A1 P00488 1/20 0.31
CA4 P22748 1/20 0.31
CA6 P23280 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13912975 0.98 TDP1 (0.41) TDP1ALDH1A1TSHRCYP2C19CYP1A2
SCHEMBL13912970 0.93 PTGS1 (0.34) TDP1ALDH1A1TSHRCYP2C19CYP1A2
SCHEMBL21088215 0.87 TSHR (0.45) ALDH1A1TSHRCYP2C19CYP1A2CA2
SCHEMBL3690416 0.85 TSHR (0.43) ALDH1A1TSHRCYP2C19CYP1A2CA2
SCHEMBL14262135 0.85 TSHR (0.43) ALDH1A1TSHRCYP2C19CYP1A2CA2
SCHEMBL10045125 0.82 CYP2C19 (0.46) ALDH1A1TSHRCYP2C19CYP1A2CA2
SCHEMBL7963768 0.82 GSR (0.35) ALDH1A1KDM4E
SCHEMBL10045123 0.82 CYP2C19 (0.45) ALDH1A1TSHRCYP2C19CYP1A2CA2
SCHEMBL23080315 0.81 ALDH1A1 (0.36) ALDH1A1TSHRKDM4EMEN1KMT2A
Hydrochloric Acid SCHEMBL6893639 0.80 GSR (0.37) ALDH1A1KDM4ESMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090062280-A1 Ophthalmic Compositions for Treating Ocular Hypertension MERCK SHARP & DOHME CORP. 2009-03-05 US disclosed
US-20090062280-A1 Ophthalmic Compositions for Treating Ocular Hypertension MERCK SHARP & DOHME CORP. 2009-03-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090062280-A1 Ophthalmic Compositions for Treating Ocular Hypertension KCNN3, KCNN1, KCNN2 TDP1 2470/4885ALDH1A1 1707/4885TSHR 3563/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.